Sue regularly reports on the latest advances in research. APL-2 is a promising treatment for dry AMD. The big news is that it’s been ‘fast tracked’ which means it’s been given priority status with the FDA who approves such things for use with patients. If you are concerned that the drug companies don’t want to develop drugs for those with AMD, Sue shares the earnings for two big companies. That means there’s…
Things have piled up for Sue. Her scotoma is getting denser, it’s been rainy and she’s sleepy, and her shared ride transportation continues to waste her time. It all adds up to…
Sue talks about 3 ways to magnify and move images to the healthy part of one’s retina, each with varying price tags. None of them halt the progression of the disease so…